Form 4: Neurogene CEO Rachel McMinn Reports Equity Awards

Neurogene Inc.'s CEO, Rachel McMinn, reported the acquisition of 25,900 restricted stock units and 155,100 stock options, alongside a correction to previously reported beneficial ownership.

Summary

• Rachel McMinn, CEO and Director of Neurogene Inc., acquired 25,900 restricted stock units (RSUs) on February 20, 2026.
• These 25,900 RSUs will vest in three equal annual installments, beginning on the first anniversary of the grant date, subject to continued service to the Issuer.
• McMinn also acquired 155,100 stock options on February 20, 2026, with an exercise price of $17.64 and an expiration date of February 20, 2036.
• One quarter of these stock options will vest on the first anniversary of the grant date, with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date.
• The filing corrects an administrative error from a previous Form 4 filed on March 28, 2025, which understated beneficial ownership by 47,500 shares.
• Following these transactions and corrections, Rachel McMinn beneficially owns 1,347,659 shares of common stock directly.
• The total beneficial ownership includes 23,900 RSUs granted on March 26, 2025 (vesting annually March 26, 2026, 2027, 2028), and 25,900 RSUs stated as granted on February 20, 2029 (vesting annually February 20, 2027, 2028, 2029).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, primarily due to the alignment of CEO incentives with shareholder interests through significant equity awards, and the correction of a previous reporting error which enhances transparency.

Positives

• Grant of 25,900 restricted stock units (RSUs) to the CEO, aligning management's interests with long-term shareholder value.
• Grant of 155,100 stock options to the CEO, providing further incentive for performance and stock price appreciation.
• Correction of a previous administrative error, ensuring accurate reporting of beneficial ownership.

Risks

• The vesting of RSUs and stock options is contingent upon Rachel McMinn's continued provision of services to Neurogene Inc., meaning forfeiture if employment ceases.
• The value realized from the stock options is dependent on the future market price of Neurogene Inc. common stock exceeding the exercise price of $17.64.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend several years into the future, indicating a long-term incentive structure for the CEO tied to the company's performance and continued service.

Management Comments

• The amount reported in Column 5 on the Reporting Person's Form 4 filed on March 28, 2025 was understated by the 47,500 shares reported as purchased by the Reporting Person on the Reporting Person's Form 4 filed on November 25, 2024. This Form 4 reflects the correct amount of common stock beneficially owned by the Reporting Person.

Industry Context

StockSavvy.ai notes that equity awards such as restricted stock units and stock options are standard components of executive compensation packages in the biotechnology and pharmaceutical industries. These awards are designed to align the interests of executives with those of shareholders by incentivizing long-term performance and stock price growth. The grants to Neurogene's CEO are consistent with typical practices for retaining and motivating key leadership in growth-oriented companies.

Comparison to Industry Standards

• The grant of RSUs and stock options to a CEO is a common practice in the biotech sector, comparable to compensation structures seen at companies like Sarepta Therapeutics or Alnylam Pharmaceuticals, where executive compensation often includes significant equity components to foster long-term commitment and performance.
• The vesting schedules, typically over three to four years, are standard for such awards, aiming to retain executives and ensure sustained focus on company growth, similar to programs at companies developing novel gene therapies.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards align the CEO's financial interests with long-term shareholder value creation. The correction of beneficial ownership ensures transparency and accurate reporting.
• Employees: The CEO's continued commitment through long-term equity incentives can signal stability and confidence in the company's future direction.

Next Steps

• Continued vesting of 25,900 RSUs in three equal annual installments beginning February 20, 2027.
• Continued vesting of 155,100 stock options, with one quarter vesting on February 20, 2027, and the remainder vesting monthly through February 20, 2030.
• Continued vesting of 23,900 RSUs granted March 26, 2025, with installments on March 26, 2026, 2027, and 2028.
• Continued vesting of 25,900 RSUs stated as granted on February 20, 2029, with installments on February 20, 2027, 2028, and 2029.

Key Dates

Recommendation

This Form 4 primarily details routine executive equity compensation and corrects a prior administrative error in beneficial ownership reporting. While the grants align management incentives with shareholder interests, they do not present new fundamental information that would warrant a change in investment thesis. The filing reinforces a 'hold' stance, awaiting more substantive operational or financial updates.

Keywords

Neurogene Inc., NGNE, Rachel McMinn, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Awards, Beneficial Ownership, CEO Compensation, Corporate Governance